title: 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
abstract: The guideline committee of Japanese Society for Dialysis Therapy (JSDT), chaired by Professor F. Gejyo of Niigata University, now publishes an original Japanese guideline entitled 'Guidelines for Renal Anemia in Chronic Hemodialysis Patients'. It includes the re-evaluation of the usage of recombinant human erythropoietin (rHuEPO) with the medical and economical arguments regarding the prognosis and the quality of life of Japanese hemodialysis patients. This guideline consists of 7 sections. The first section comprises the general definition and the differential diagnosis of anemia. The hemoglobin (Hb) level of the Japanese population seemed to be low when compared with that of the European and American populations. The second section describes the target Hb level in hemodialysis patients. Multivariate analysis of the data that were collected from dialysis institutions throughout the country showed that an Hb level of 10-11 g/dL (Ht level 30-33%) at the first dialysis session in a week is the ideal range for chronic hemodialysis patients in terms of the 3-5 year survival rate. The supine position at blood sampling and the sampling timing at the first dialysis session in a week might affect the lower setting of target Hb hematocrit (Ht), compared to that of European and American guidelines. However, we particularly recommended that an Hb level of 11-12 g/dL (Ht level from 33 to 36%) at the first dialysis session in a week is desirable in relatively young patients. In the third section, the markers of iron deficiency are discussed. The Transferin saturation test (TSAT) and serum ferritin were emphasized as the standard markers. The routes of administration of rHuEPO and its dosages are written in the fourth section. The subcutaneous route was associated with the occurrence of secondary red cell aplasia due to anti-rHuEPO antibodies; however, secondary red cell aplasia was seldom observed in the venous injection. From this fact we recommend venous injection for chronic hemodialysis patients. We advocate an initial dosage of 1500 U three times per week. The fifth section deals with the factors refractory to treatment with rHuEPO. If the patient shows an inadequate response to the usage of 9000 U per week, this condition defines the inadequate response to rHuEPO in Japan. Blood transfusion must be avoided where possible. The reasons for this and the adverse effects are interpreted in section six. In the final section, the adverse effects of rHuEPO are listed. Among them, hypertension, thrombotic events and secondary red cell aplasia were emphasized as the major complications.
authors.affiliation: Graduate School of Medical and Dental Sciences, Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata 951-8520, Japan.
authors.forename: Fumitake
authors.initials: F
authors.lastname: Gejyo
authors.forename: Akira
authors.initials: A
authors.lastname: Saito
authors.forename: Tadao
authors.initials: T
authors.lastname: Akizawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Akiba
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Sakai
authors.forename: Masashi
authors.initials: M
authors.lastname: Suzuki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nishi
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Tsubakihara
authors.forename: Hideki
authors.initials: H
authors.lastname: Hirakata
authors.forename: Masami
authors.initials: M
authors.lastname: Bessho
mesh_terms: D000740:Anemia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D018798:Anemia, Iron-Deficiency / Q000175:diagnosis; D001803:Blood Transfusion; D003937:Diagnosis, Differential; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D019190:Iron Overload / Q000175:diagnosis; D007564:Japan; D007676:Kidney Failure, Chronic / Q000628:therapy; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects / Q000592:standards*; D012955:Societies, Medical; D017211:Treatment Failure
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin